Breakthrough ALS Research at Washington University

View Content

Dr. Miller featured in news article and video about his Phase I clinical trial of antisense oligonucleotides targeting the SOD1 protein in ALS patients with SOD1 mutations. “We can do go in a technique called antisense oligo nucleotides and  take that small mistake in those RNA instructions and like a small eraser and go in an erase that mistake and fix it.” said Dr. Timothy Miller.